Reshaping treatment paradigm in actinic keratosis by using a modified Delphi questionnaire
Key findings emphasize the importance of patient-centered approaches and treatment attributes beyond efficacy (e.g. tolerability or adherence). Understanding the mechanisms of action of treatments is vital for managing patients' and clinicians' expectations and optimizing outcomes. Alternative strategies for evaluating efficacy, including the Actinic Keratosis Area and Severity Index (AKASI) score and lesion reduction from baseline, were also highlighted.
Authors
- Lara Ferrándiz
- Yolanda Gilaberte (ORCID: https://orcid.org/0000-0001-8034-3617)
- Ina Hadshiew
- Thomas Dirschka (ORCID: https://orcid.org/0000-0001-7804-5311)
- Marco Ardigò (ORCID: https://orcid.org/0000-0002-5772-4937)
- Maria Concetta Fargnoli (ORCID: https://orcid.org/0000-0002-7249-2556)
- Rolf‐Markus Szeimies (ORCID: https://orcid.org/0000-0002-8452-0737)
- Ketty Peris (ORCID: https://orcid.org/0000-0003-1957-6600)
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Hebron University (PS)
- Humanitas University (IT)
- Universidad de Zaragoza (ES)
- Agostino Gemelli University Polyclinic (IT)
- Knappschaftskrankenhaus Recklinghausen (DE)
- Instituto de Investigación Sanitaria Aragón (ES)
- San Gallicano Hospital (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- IRCCS Humanitas Research Hospital (IT)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1080/09546634.2025.2487657
- Citations
- 1
- Primary Topic
- Nonmelanoma Skin Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Sanofi
- L'Oreal USA
- Biogen
- Regeneron Pharmaceuticals
- Les Laboratories Pierre Fabre
- Mylan
- Recordati Rare Diseases
- Incyte
- Galderma
- Sun Pharma
- European Academy of Dermatology and Venereology
- NeraCare
- Almirall
- LEO Pharma
- UCB Pharma
- Cilag